ASCO23 Day 3 :Parp Inhibitors & Late Breaking Abstract session

While there were fewer gynecologic cancer sessions on Day 3, Sunday June 4th there were two important sessions regarding the use of PARP inhibitors and trial results for a drug to teat  platinum resistant ovarian cancer drug which may be change practice.

Parp Inhibitor Optimal Selection and Toxicity Management 

Dr Tew - Status updates on Parp use

Dr Friedlander- Real World Experience in Managing PARP Toxicities 

 

 

 Susan Feinberg  (FORCE) - Living on a PARPi 

 

Late Breaking Abstract Session  

Mirvetixumab in Folate Receptor Alpha positive platinum resistant ovarian cancer

I wish I had been able to be in the room when this session took place. I could feel the excitement from the Tweets being posted.  This is the first trial to show overall survival benefit in platinum resistant ovarian cancer! This is practice changing. 

Wow! Amazing to see an #OverallSurvival benefit for Mirvetuximab for patients with platinum resistant #OvarianCancer
🚨 new standard of care alert 🚨 #GynCSM #ASCO23
Congrats to the investigators and patients who made this #research possible! @ASCO pic.twitter.com/ojYBIDKYS0

— Megan Hutchcraft MD (@MeganLeigh127) June 4, 2023

🚨Amazing to see ⬆️ in overall survival for mirvetixumab in FOLR1 positive platinum resistant #ovariancancer. Absolutely new standard of care!! 👏 #gyncsm #ASCO23 pic.twitter.com/yweWSh5qES

— Eleonora Teplinsky, MD (@drteplinsky) June 4, 2023

I shared tweets others wrote about the MIRASOL trial (mirvetixumab in FOLR1 positive platinum resistant #ovariancancer ) but... this slide says it all . #ASCO23 #gyncsm pic.twitter.com/Sif0gn76a8

— Dee Sparacio (@womenofteal) June 4, 2023

 Here is a slide of the overall survival  MIRV 16.46 months vs investigator choice of treatment 12.75 months.

 Stop by tomorrow for highlights from my last day of ASCO - Day 4 . 

Dee

Every Day is a Blessing

2021 SGO Virtual Annual Meeting Saturday March 20

Here are highlights from the Virtual #SGOmtg sessions I attended on Saturday March 20, 2021. 

The morning began with a wonderful get-together for Patient Advocates at a 9am session. I am so glad to see patient advocates play a role in so many aspects of the SGO organization.

 In real time, I shared information on Twitter( @womenofteal) about the sessions I attended using the #gyncsm and #SGOmtg hashtags

 Surgery:

Scientific Plenary II: Cutting Edge - Advancing Surgical Innovation -If Looks Could Kill: Morphologic Subtypes of High-Grade Serous Ovarian Cancer
Dr Katelyn Handley- Looking at morphology and molecular difference in OC #SGOMtg #gyncsm #SGOPatAdv pic.twitter.com/LavQt2RBLp

— Dee Sparacio (@womenofteal) March 20, 2021

Higher Surgical Volume is Associated with Better Outcomes for Frail Patients Undergoing Surgery for Ovarian Cancer- M. Nakhla #SGOMtg #gyncsm pic.twitter.com/3ZU7q8KZ0R

— Dee Sparacio (@womenofteal) March 20, 2021

MEDSCAPE shared this article on MIS and interval debulking surgery. https://www.medpagetoday.com/meetingcoverage/sgo/91738

Equity 

Education Forum V: Eradicating Racism and Discrimination in Medicine Thank you Dr Latimore. #SGOMtg #gyncsm
Have you ever taken a test to measure your implicit bias? I have. Results were not what I expected. We can do better. "See people as an individual." pic.twitter.com/bCEYQ1IDiY

— Dee Sparacio (@womenofteal) March 20, 2021

Education Forum V: Eradicating Racism and Discrimination in Medicine #SGOMtg #gyncsm
Dr Marsh
"We have to see it."
"Honesty is more important than fear"
We need to do this now. pic.twitter.com/48BS8u4I2B

— Dee Sparacio (@womenofteal) March 20, 2021

How to address our own biases? We needs to address our own biases while addressing bigger picture in our society! #SGOMtg #sgo2021 @SGO_org @somedocs #MedTwitter #obgyntwitter #gyninfluencer pic.twitter.com/Kk20tx51YD

— Payam Katebi Kashi, MD, PhD (@PayamKashiMD) March 20, 2021

PAOLA-1 Olaparib plus Bev

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
HR repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial
E. Pujade-Lauraine#SGOMtg #gyncsm pic.twitter.com/sEUkrDBAzJ

— Dee Sparacio (@womenofteal) March 20, 2021

Tumor infiltrating lymphocytes

Great job @AmirJazaeri - impressive response of #cervicalcancer to TIL therapy with LN-145! Responses were durable and median duration of response was not reached. #SGOMtg #gyncsm pic.twitter.com/QDaLusnqv3

— Shannon Westin (@ShannonWestin) March 20, 2021

Great job @AmirJazaeri - impressive response of #cervicalcancer to TIL therapy with LN-145! Responses were durable and median duration of response was not reached. #SGOMtg #gyncsm pic.twitter.com/QDaLusnqv3

— Shannon Westin (@ShannonWestin) March 20, 2021

Keynote 158 Cervical Cancer

Updated data from the KEYNOTE-158 study of pembrolizumab in recurrent #cervicalcancer - response rate of 17% in pts with PD-L1 positive tumors. Median time to response was 2 months- fast acting! Med duration of response not reached... #SGOMtg #gyncsm pic.twitter.com/ut0EinNBvy

— Shannon Westin (@ShannonWestin) March 20, 2021

 

Scientific Plenary III: Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study
H. Chung#SGOmtg #gyncsm pic.twitter.com/qdBegPgXfZ

— Dee Sparacio (@womenofteal) March 20, 2021

 ENGOT-OV 16/ NOVA  niraparib

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Dr Matulonis
ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian #SGOmtg #gyncsm pic.twitter.com/wwd9DwuTho

— Dee Sparacio (@womenofteal) March 20, 2021

PARP Inhibitor duration of follow-up

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials Bradley
Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Longest duration of follow -up of a PARP inhibitor in trials to date. #SGOmtg #gyncsm pic.twitter.com/hFNBwgsZ5K

— Dee Sparacio (@womenofteal) March 20, 2021

Cervical Cancer Radiation study

#SGOmtg
Translational Research 2021:
Genomic profiling of adv cervical cancer to predict response to PD-1 inhibitor combination therapy: a secondary analysis of the CLAP trial #gyncsm
C. Lan
predictive Biomarker research for cervical cancer pic.twitter.com/IuoDprILOi

— Dee Sparacio (@womenofteal) March 20, 2021

Phase III Ran Trial of Postoperative Adjuvant Conventional Radiation (3DCRT) vs Image Guided Intensity Modulated Radiotherapy (IG-IMRT) in Cervical Cancer (PARCER)
S. Chopra
Reduction in diarrhea, #sgomtg#gyncsm pic.twitter.com/iGgp0EEcdF

— Dee Sparacio (@womenofteal) March 20, 2021

Shared Decision Making Tool

Niraparib as Maintenance Therapy- Dr Matalunis https://ascopost.com/videos/sgo-2021-virtual-annual-meeting-on-womens-cancer/ursula-matulonis-on-ovarian-cancer-niraparib-as-maintenance-therapy/

Priority Assessment for Women with Recurrent Ovarian Cancer: A Pilot Study presented by @StephanieVBlank Aids shared-decision making! Feasible with 97% completion! Next steps: Ongoing assessments, electronic version, languages #SGOmtg #SGOPatAdv #GYNcsm pic.twitter.com/hF4ntyzCwk

— Annie Ellis (@Stigetta) March 21, 2021

TY patients 4 insights Priorities Assessment Tool! Prior work https://t.co/O8UAvCtEKC https://t.co/COvGQgQJeN revealed needs-Standardized way 2 individualize tx discussions &capture changes tx goals/priorities along care continuum @MelissaFrey2 @StephanieVBlank #SGOmtg #SGOPatAdv pic.twitter.com/QDhiPDc8vs

— Annie Ellis (@Stigetta) March 21, 2021

Stop by tomorrow for my Sunday highlights.  

Dee

Every Day is a Blessing!

SGO meeting Tuesday

Here are the top tweets from the SGO meeting on Tuesday!  

Treating the Whole Patient

If no one talks about it, we aren’t treating the WHOLE patient. Break through the barriers. Sexual health is part of our responsibility as female health providers. #SGOmtg #SGOHawaii50 pic.twitter.com/vsotOJjxoZ

— Kristin Koerten (@KMKoerten) March 19, 2019

Patient Perspective on Clinical Trials

Yes- Thank-you Mary for educating us re patients’ concerns. So important for us as we design #clinicaltrials! #sgomtg @gyncsm https://t.co/H9nLSFC2JI

— Bhavana Pothuri (@BPothuri) March 19, 2019

 Maintenance Olaparib

Maintenance Olaparib May Be More Cost-Effective Than Bevacizumab in iBRCA/i-Mutant Ovarian Cancer #SGOMtg https://t.co/Rm4QL3GoD1

— SGO (@SGO_org) March 19, 2019

GAS6 and chemoresistance

#SGOMtg learns increased GAS6 assoc w/ #chemoresistance & lower #PFS in patients w/ high-grade #OvarianCancer

Chemo + anti-GAS6 AVB-500 decreases #tumor burden, tumor & stromal cell viability in mouse #PDX #modelhttps://t.co/7aGWxrQUsR#oncology #immunotherapy #antibody pic.twitter.com/IMZo1s0rrO

— DDNews Online (@DDNewsOnline) March 19, 2019

Immunotherapy

Dendritic cell-based immunotherapy (DCVAC/OvCa) with chemotherapy in patients with platinum-sensitive, relapsed, epithelial ovarian carcinoma: Survival analysis of a phase II, open-label, randomized, multicenter trial (study SOV02). #SGOMtg https://t.co/HZEMOBK9Bj

— SGO (@SGO_org) March 19, 2019

Wonderful distillation of immunotherapy session by @KunleOdunsiMD of @RoswellPark including where research needs to go in future. Biomarkers predicative of response needed! #sgomtg #gyncsm pic.twitter.com/azdssh7opw

— Annie Ellis (@Stigetta) March 19, 2019

Dr. Cibula presents survival analysis of SOV02 Dendritic Cell Vaccine in ovarian cancer #sgomtg #gyncsm pic.twitter.com/Rw7ZwceAWq

— Annie Ellis (@Stigetta) March 19, 2019

Cisplatin/Gemzar/Pembrolizumab

#SGOmtg Cis/gem/pembro tolerable, but no durable response in platinum-R #ovariancancer. Unfortunately another study showing limited efficacy of #checkpointinhibitors in ovarian cancer.… https://t.co/Hd7oUN7Lz9

— Deanna Teoh, M.D., M.S., FACOG, FACS (@DeannaTeoh) March 19, 2019

Next year's meeting is in Toronto. And the gavel has passed to Dr Huh!

Proud & Honored to “pass the gavel” of leadership to
Dr. Warner Huh , 51st President of SGO at #SGOmtg . Welcome Dr Huh -a Courageous Warrior in our Fight to Eradicate GYN Cancer ! pic.twitter.com/UcpNL9dJRU

— Carol Brown (@drcarolbrownMSK) March 19, 2019

Thank you to  @KMKoerten , @Stigetta, @DeannaTeoh , @drcarolbrownMSK , @SGO_org, @DDNewsOnline, @BPothuri for tweeting from the meeting!


Dee
Every Day is a Blessing!

#SGOmtg Twitter Highlights - Research Highlights Monday, March 26, 2018

Monday March 26th was another day of important presentations at the SGO Annual meeting. Some results may change treatment protocols going forward.

Here are the tweets I found of most importance.

Cervical Cancer - Minimally invasive surgery *this one may change how early cervical cancer is treated

Do we need to rethink minimally invasive surgery for cervix? #SGOMtg pic.twitter.com/XTLgg5IO0t

— Erin Stevens (@erinstevensmd) March 26, 2018

Dr Raih Hain of @MDAndersonNews presenting surprising results- our patients with early #cervicalcancer have been doing worse since the adoption of min invasive surgery. Time to rethink practice at the #SGOMtg pic.twitter.com/K3afaUynxe

— Dr. Robert Dood (@DrRobDood) March 26, 2018

Ovarian Cancer Debulking Surgery

No residual disease remains a goal of OvCa debulking surgery. Single site optimal improves PFD and OS as compared to multisite optimal or suboptimally debulked OVCA. Manning-Geist et al #SGOMtg pic.twitter.com/KP0P9SeEAK

— Rick Boulay,MD (@journeycancer) March 26, 2018

Excellent talk on #ovariancancer surgery by @AnilSoodMD at the #SGOMtg @SGO_org @MDAndersonNews pic.twitter.com/IiXT5YbBG2

— Kathleen Schmeler MD (@kmschmeler) March 26, 2018

Ovarian Cancer - Niraparib and Pembrolizumab

Late Breaking Abstract: Dr. Konstatinopoulos presents results of niraparib and pemrolizumab combo in heavily pretreated platinum resistant ovarian cancer #SGOmtg #gyncsm pic.twitter.com/zWhSRVAhx4

— Annie Ellis (@Stigetta) March 26, 2018

Ovarian Cancer - Olaparib and Durvalumab

Olaparib + durvalumab ORR of 72% in plt sens recurrent #ovariancancer gBRCA pos patients #SGOMtg pic.twitter.com/hio2vSVxmM

— Alpa Nick (@AlpaNick) March 26, 2018

Late Breaking Abstract session: Dr. Drew presents results of MEDIOLA basket trial of olaparib and durvalumab combo in relapsed BRCA+ platinum sensitive ovarian cancer #SGOmtg #gyncsm pic.twitter.com/lycZZlxYYR

— Annie Ellis (@Stigetta) March 26, 2018

 Ovarian Cancer- Metastasis and DDR2 experssion

M Greenwade presents work to understand stromal expression of DDR2 and control ovarian cancer metastasis #SGOmtg #gyncsm pic.twitter.com/wGE4w44Qaf

— Annie Ellis (@Stigetta) March 26, 2018

Palliative care

Palliative care: not just for end of life. New model includes life prolonging care from diagnosis. Very important for QoL throughout treatment and beyond! #SGOMtg #gyncsm pic.twitter.com/tyGDFxkACz

— Annie Ellis (@Stigetta) March 25, 2018

Survivorship / BMI and Risk

Endometrial cancer is one of the 3 obesity-driven cancers in women. Only 1% of #endometrial and #ovarian cancer patients are meeting the 2006 ACS guidelines for #cancersurvivors - Dr. Von Gruenigen #SGOMtg pic.twitter.com/EAX08fQOqN

— Ali Saiz (@aulyouneedisluv) March 26, 2018

Fantastic sunrise seminar on survivorship! Survivors need to be empowered with information after front line treatment. Reduce risk and screen for secondary cancers. #sgomtg #gyncsm pic.twitter.com/OLyOW0E4lL

— Annie Ellis (@Stigetta) March 26, 2018

Lay navigation

Lay navigation (non clinical) for pts w/ gyn cancers. Navigation triggered via distress scores/risk factors, then triage pt to resources. Study: how did this service impact cost? 1052 patients; 37% navigated. Navigated pts=57% ⬇ in total costs & ⬇ in hospitalization#SGOmtg

— Erica Bednar (@EMBOSU) March 26, 2018

Granulosa Cell tumors

Excellent presentation by @RTylerHillmanMD identifying KMT2D mutations in granulosa cell tumors #SGOMtg pic.twitter.com/EhcSeeq3ci

— Aaron Shafer (@aaronshafer99) March 26, 2018

@RTylerHillmanMD presents high quality sequencing used to identify KMT2D predicting recurrence in granulosa cell #ovariancancer @MDAndersonNews #SGOMtg pic.twitter.com/imZZcpSYuz

— Dr. Robert Dood (@DrRobDood) March 26, 2018

Thanks Dr Dood, Erica Bednar, Annie Ellis, Ali Saiz, Alpa Nick, Rick Boulay, Erin Stevens and Kathleen Schmeler for sharing on Twitter during the meeting.

Dee
Every Day is a Blessing!

SGO Meeting Highlights via Twitter ~ Day Three, March 14, 2017

I am at home watching the snow fall and following Tweets from The Society of Gynecologic Oncology (@SGO_org) Annual Meeting using the hashtag #SGOmtg.

Here are some tweets fromTuesday, March 14,2017 ( Pi day!)

Other sources of Meeting coverage:

Stay up to date on the #SGOMtg with our conference coverage! https://t.co/dzpWAtqAlW

— CURE Magazine (@cure_magazine) March 14, 2017

Endometrial Cancer

MMR Deficiency Linked to PD-L1 Expression in Endometrial Cancer https://t.co/E0LI2OzxDO #SGOmtg

— OncLive.com (@OncLive) March 14, 2017

Sentinel lymph mode mapping is #costeffective for the treatment of #endometrial cancer! #SGOMtg #gyncsm #endcancer great job @SuidanRudy https://t.co/uZxo7RB7NV

— Shannon Westin (@ShannonWestin) March 14, 2017

Ovarian cancer
GOG-3003 Compares pegylated liposomal doxorubicin (PLD) to PLD in combination with motolimod (a new type of investigational drug that stimulates the immune system)

Motolimod is an agonist for TLR8 in GOG-3003. Combo with PLD in #ovariancancer had no improvement in OS or PFS. #SGOMtg

— Rebecca Previs (@BeccaPrevisMD) March 14, 2017

     SOLO2 Trial studied LYNPARZA as maintenance treatment for women with BRCA-mutated metastatic ovarian cancer

SOLO2 primary endpoint was PFS, not OS (key secondary endpt) #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

SOLO2 data presented at #SGOMtg: PFS advantage in olaparib maintenance arm for BRCAmut recurrent ovary cancer. Compelling. #parpi

— Jenny Mueller MD (@JennyMueller_) March 14, 2017

SOLO2:  Time to First Secondary Treatment- 27.9 months vs 7.1 (HR 0.28; p <0.0001) in favor of olaparib -  WOW!!!! #SGOMtg

— Tabari (@Tabari_B) March 14, 2017

37% using olaparib had a grade 3 or higher adverse event (vs 18% with placebo) #SOLO2 #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

GOG-212

Late breaking abstract time. First up GOG212. #SGOmtg pic.twitter.com/qcprT7KBBp

— Annie Ellis (@Stigetta) March 14, 2017

#SGOMtg #GOG212: example that more treatment is not always better.No improvement in OS despite slight PFS improvement.

— Deanna Teoh, M.D. (@DeannaTeoh) March 14, 2017

GOG212: Surveillance v Taxol x12 vs CT2103 x12. Primary endpoint OS. #SGOMtg Activated 12 years ago!

— Don S Dizon (@drdonsdizon) March 14, 2017

Both Taxol and CT-2103 showed clinically meaningful and worse neurotoxicity vs surveillance in GOG212 @copebuckeye #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

Stress

Fascinating research approach integrating basic science and big database looking at drug combo and stress in ov ca from @DrRobDood #SGOMtg pic.twitter.com/fsn0nB0ptE

— Katie Kurnit (@katiekurnit) March 14, 2017

Uterine Carcinosarcoma

TP53 mutations are most common in our study of carcinosarcoma #uterinecancer @nicoleflemingmd #endcancer #SGOMtg pic.twitter.com/maPL5RROhA

— Rebecca Previs (@BeccaPrevisMD) March 14, 2017

Cervical Cancer
AXAL :Phase 2 study axalimogene filolisbac (AXAL), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix 

Improved OS over historical controls with AXAL in recurrent #cervical cancer! Big news.  #SGOMtg #gyncsm https://t.co/whlS6QOBBi

— Shannon Westin (@ShannonWestin) March 14, 2017

AXAL: live attenuated listeria based immnotherapy that secretes HPV-16 E7 protein fused with a truncated fragment of listeriolysin O #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

General

#quality research improves outcomes!  Reduced blood transfusions = less cost and better outcomes. Great job @LPrescottMD #SGOMtg #gyncsm https://t.co/FJpqGHRDXe

— Shannon Westin (@ShannonWestin) March 14, 2017

Sunrise Session. Dr. Annunziata says Phase 2/3 trials and inclusion of biomarker targeting/analysis are the future #SGOMtg

— A.C. Evans, MD, PhD (@gynoncdoc) March 14, 2017

So thankful for a glimpse via tweets of research that can change the future of women with gynecologic cancers.

Dee
Every Day is a Blessing!

Ovarian Cancer Treatment: Targeted Therapy

In recent years the FDA has approved a number of targeted therapy drugs for the treatment of ovarian cancer.
"Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer. "

Some targeted therapies interfere with proteins or receptors in ovarian cancer cells and stop their growth and others will prevent the growth of blood vessels which supply the cancer cell.

Bevacizumab ( Avastin)
"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels. "NCI definition

Bevacizumab may be used along with carboplatin and paclitaxel as an option for women with Stage III, IV ovarian cancer as well as for women with a recurrence. ( NCCN guidelines)  

Olaparib (Lynparza)
"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks. "NCI definition


This oral treatment is approved for women with advanced ovarian cancer who have the BRCA1 or BRCA2 mutations and have had 3 prior chemotherapy treatments.

Dee
Every Day is a Blessing!


Sources:
http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/ovarian-cancer/treatment/index.html
NCI :http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet#q1

ASCO - Parp Inhibitor and BRCA Mutation Studies

Part Three of my ASCO Report.

 Parp inhibitors (which inhibit the enzyme  poly ADP ribose polymerase) have been found in some cases to be effective in women with BRCA1 and 2 mutations. There have even been a few studies where the inhibitor was found to be effective in women without the mutation.

The Parp inhibitor abstract and BRCA 1& BRCA 2 abstract  were part of an ASCO Poster Session, while the last study was part of an Oral Abstract session I attended.

Abstract 5068
A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study.

This Spanish study was discontinued early since the clinical benefit number was not reached due to the lack of activity of Pazopanib.

Abstract 5066

Effect of BRCA mutation on prognosis in patients with ovarian cancer: A systematic review and meta-analysis.

This poster was a review of over 2000 studies and confirmed the hypothesis that a BRCA mutation is a prognostic ( predicting the outcome)  factor in patients with ovarian cancer. Those women with BRCA mutations had better survival than the control group (women without the mutation). There was slightly longer survival for those with BRCA 2 mutations than BRCA1 . The researchers suggested that was due to a different nature of the dysfunction of these two genes.


Abstract 5001

Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.

This abstract was discussed by Dr Oza at the Oral Abstract session on Saturday. The study involved women with recurrent disease. Olaparib is an oral Parp Inhibitor drug.
Conclusion:  Patients with platinum sensitive recurrent serous ovarian cancer who took the parp inhibitor olaparib along with carboplatin and placitaxel followed by olaparib maintenance had some improvement in progression free survival (median 2.6 months) compared to patients treated with carboplatin and paclitaxel online.

It should be noted that earlier this year Astra Zeneca ( the maker of Olaparib) decided not to produce Olaparib for maintenance therapy of serous ovarian cancer.

Dee
Every Day is a Blessing!

ASCO Preview - Two interesting Studies

The ASCO meeting abstracts are posted online. Here are two studies highlighted on Cancer.net.

Long-Term Treatment with Olaparib May Help Treat Recurrent Ovarian Cancer

This PARP inhibitor is effective in extending the progression-free survival of recurrent patients with an inherited version of a DNA deficiency as well as a non-inherited version. Interesting study. I can't wait to hear more about olaparib. Here is a Med-Page link that explains the study further.

Screening Does Not Reduce Deaths from Ovarian Cancer for the General Population

This large ( 80,000 particpant) study highlights the need for further research to find a a screening test for the general public for ovarian cancer. CA-125 and Ultrasound together to screen for the disease did not reduce mortality numbers.

Dee

Every Day is a Blessing!